Primary hepatic osteosarcoma (PHOS) represents an exceptionally rare and aggressive subtype of extraskeletal osteosarcoma. This malignant tumor originates directly within the liver parenchyma without any primary skeletal involvement. Statistically, less than 1% of all extraskeletal osteosarcomas occur in the liver. Consequently, clinicians often face significant diagnostic challenges when these patients present with large abdominal masses and a poor prognosis.

Diagnostic Significance of Primary Hepatic Osteosarcoma on Imaging

A recent case involving a 64-year-old man highlights the complexity of primary hepatic osteosarcoma. Multimodal imaging, including CT, MRI, and PET/CT, revealed a massive heterogeneous hepatic mass measuring 163×128×160 mm. The scans demonstrated extensive calcifications and a distinct cloud-like rim enhancement. Notably, the PET/CT showed elevated F-18-FDG uptake, while bone scintigraphy confirmed the absence of primary skeletal lesions. These findings are crucial for differentiating PHOS from more common conditions like hepatocellular carcinoma or metastatic bone cancer.

Furthermore, the radiologic-pathologic correlation plays a vital role in diagnosis. The cloud-like enhancement observed on imaging often corresponds to unmineralized osteoid and significant vascular proliferation. In this specific case, the patient also presented with pulmonary and lymph node metastases, underscoring the tumor's high malignancy. Physicians must utilize comprehensive imaging to map the extent of the disease and plan individualized interventions.

Pathological Profiling and SATB2 Expression

Histopathological analysis remains the gold standard for confirming a PHOS diagnosis. Biopsy samples typically show atypical mesenchymal cells producing an osteoid matrix. Furthermore, immunohistochemical profiling revealed strong positivity for special AT-rich sequence-binding protein 2 (SATB2). This marker is highly sensitive for osteoblastic differentiation. Additionally, the tumor tested negative for epithelial markers, which helped rule out other hepatic malignancies.

The pathogenesis of PHOS likely involves the metaplasia theory, where mesenchymal cells undergo malignant transformation into bone-forming cells. Because evidence-based guidelines are limited due to the disease's rarity, management usually requires a combination of radical surgery and adjuvant therapies. Early detection through advanced imaging and precise pathological evaluation offers the only chance for improved patient outcomes.

Frequently Asked Questions

What is primary hepatic osteosarcoma?

It is an extremely rare malignant tumor that develops in the liver without a primary lesion in the bones. It is known for its aggressive nature and rapid progression.

How do doctors differentiate PHOS from other liver cancers?

Doctors use a combination of CT, MRI, and PET/CT to look for specific calcification patterns. Pathological testing for the SATB2 marker and the presence of an osteoid matrix are also definitive diagnostic steps.

What are the common treatment options for PHOS?

Treatment typically involves surgical resection of the tumor whenever possible. Due to the high risk of recurrence, clinicians often recommend adjuvant chemotherapy or radiation, though standardized protocols are still evolving.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Zhu H et al. Giant primary hepatic osteosarcoma: A rare case report and review of the literature. Hell J Nucl Med. 2026 Apr 20. doi: undefined. PMID: 42001442.

Baheti AD et al. Extraskeletal osteosarcoma: imaging features and review of the literature. Skeletal Radiol. 2015;44(11):1553-1563.

Thampi S et al. Primary hepatic osteosarcoma: A case report. J Clin Exp Hepatol. 2014;4(2):175-177.